Skip to content
61.25 USD -0.43% -0.27
OPEN 61.39
DAY RANGE 61.39 - 61.10
52 WEEK RANGE 86.29 - 60.71
Interactive Brokers Logotype

Buy INCY stocks now with Interactive Brokers – the most advanced investment platform

Valuations metrics

Market capitalization 13.7B
Enterprise value 10.6B
Trailing pe 42.715275
Forward pe 13.115138
Peg ratio 13.115138
Price to sales ttm 3.9544246
Price to book mrq 3.0745776
Enterprise to revenue 3.061
Enterprise to ebitda 18.452


Fiscal year ends 2022-12-31
Most recent quarter 2023-03-31
Profit margin 0.09348
Operating margin 0.14466
Return on assets ttm 0.05782
Return on equity ttm 0.07792
Income statement
Revenue ttm 3.5B
Revenue per share ttm 15.602
Quarterly revenue growth 0.103
Gross profit ttm 1.6B
Ebitda 587.9M
Net income to common ttm 324.4M
Diluted eps ttm 1.44
Quarterly earnings growth yoy -0.429
Balance sheet
Total cash mrq 3.1B
Total cash per share mrq 13.953
Total debt mrq 40.2M
Total debt to equity mrq 0.902
Current ratio mrq 3.948
Book value per share mrq 20.006
Cash flow
Operating cash flow ttm 648.6M
Levered free cash flow ttm 523M

Stock statistics

Shares outstanding 223.1M
Float shares 185.7M
Avg 10 volume 1.8M
Avg 30 volume 1.8M
Shares short 7M
Short ratio 3.55
Short percent of shares outstanding 0.0377
Percent held by insiders 0.015319999
Percent held by institutions 0.96510005

Stock price summary

Fifty two week low 60.71
Fifty two week high 86.29
Fifty two week change -14.948
Beta 0.716045
Day 50 ma 68.7496
Day 200 ma 74.2045

Dividends and splits

Last split factor 2-for-1 split
Last split date 2000-09-01

Incyte (INCY) company profile

Incyte Corp. (NASDAQ: INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics. The company’s lead drug, Jakafi, treats two types of rare blood cancer and graft. Its portfolio entails compounds in various stages, ranging from preclinical to late-stage development and commercialized products.